hotspot -WSS

hotspot

author：focus 2025-10-02 05:01:07 - browse：67

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Why age limits for politicians are a terrible idea

focus

WSS

Health insurers say they are turning to AI to cut costs, improve care

Chemotherapy drug shortage eases slightly but still widespread

Physician executives need more than on

Sana to lay off nearly a third of staff, de

Senate panel eyes new effort on drug shortages

Childbirth

entertainment

hotspot

entertainment

Continuity nursing helped my family in our darkest PICU moments

The future of health care in the House

Hollywood unions extend contract negotiations for actors

First Opinion Podcast: What happens when kids become caregivers?

Bright Health sells Medicare Advantage business to Molina

Why age limits for politicians are a terrible idea

Jerome Adams on the need for new antivirals for Covid

Phenylephrine and the overlooked value of the placebo effect

Novavax promises a turnaround & Lilly roils the obesity market

Health insurers say they are turning to AI to cut costs, improve care

hotspot

Bill would stop addiction treatment from triggering child abuse inquiry

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Average age of first period drops to 11.9 years, study shows

When women are denied an abortion, their children fare worse than peers

Addiction doctors spar with methadone clinics over legislation

entertainment

focus

leisure time

leisure time